431 related articles for article (PubMed ID: 8452705)
1. [The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease].
López Morante AJ; Sáez-Royuela F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C
Rev Esp Enferm Dig; 1993 Jan; 83(1):5-9. PubMed ID: 8452705
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
4. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease].
Vucelić B; Krznarić Z; Sentić M; Milicić D; Korać B; Cvorisćec D; Stavljenić A
Lijec Vjesn; 1990; 112(9-10):281-4. PubMed ID: 2093781
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
6. [Application of chosen granulocyte markers in diagnostics of Leśniowski-Crohn's disease and ulcerative colitis--preliminary research].
Fedak D; Pawlica D; Ciećko-Michalska I; Solnica B; Mach T
Przegl Lek; 2010; 67(2):114-8. PubMed ID: 20557011
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis.
Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F
Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593
[TBL] [Abstract][Full Text] [Related]
8. [Serum acute phase proteins for determining disease activity of ulcerative colitis and Crohn disease].
Vucelić B; Milicić D; Krznarić Z; Korać B; Sentić M; Hadzić N; Stavljenić A; Cvorisćec D
Acta Med Austriaca; 1991; 18(4):100-5. PubMed ID: 1722373
[TBL] [Abstract][Full Text] [Related]
9. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Folwaczny C; Wiebecke B; Loeschke K
Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
[TBL] [Abstract][Full Text] [Related]
10. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
11. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis.
Zilberman L; Maharshak N; Arbel Y; Rogowski O; Rozenblat M; Shapira I; Berliner S; Arber N; Dotan I
Digestion; 2006; 73(4):205-9. PubMed ID: 16837810
[TBL] [Abstract][Full Text] [Related]
12. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
14. Resistin is an inflammatory marker of inflammatory bowel disease in humans.
Konrad A; Lehrke M; Schachinger V; Seibold F; Stark R; Ochsenkühn T; Parhofer KG; Göke B; Broedl UC
Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1070-4. PubMed ID: 17998831
[TBL] [Abstract][Full Text] [Related]
15. Paediatric inflammatory bowel disease in New Zealand.
Yap J; Wesley A; Mouat S; Chin S
N Z Med J; 2008 Oct; 121(1283):19-34. PubMed ID: 18841182
[TBL] [Abstract][Full Text] [Related]
16. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.
Becker K; Berger M; Niederau C; Frieling T
Hepatogastroenterology; 1999; 46(28):2309-14. PubMed ID: 10521988
[TBL] [Abstract][Full Text] [Related]
17. Platelet activating factor in stool from patients with ulcerative colitis and Crohn's disease.
Hocke M; Richter L; Bosseckert H; Eitner K
Hepatogastroenterology; 1999; 46(28):2333-7. PubMed ID: 10521992
[TBL] [Abstract][Full Text] [Related]
18. Relationships between clinical data and histology of the large bowel in Crohn's disease and ulcerative colitis.
Schmitz-Moormann P; Himmelmann GW; Brandes JW
Pathol Annu; 1985; 20 Pt 1():281-301. PubMed ID: 3991239
[TBL] [Abstract][Full Text] [Related]
19. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases.
Jung YS; Park JJ; Kim SW; Hong SP; Kim TI; Kim WH; Cheon JH
Dig Liver Dis; 2012 Nov; 44(11):897-903. PubMed ID: 22721842
[TBL] [Abstract][Full Text] [Related]
20. CARD15 mutations in Dutch familial and sporadic inflammatory bowel disease and an overview of European studies.
van der Linde K; Boor PP; Houwing-Duistermaat JJ; Crusius BJ; Wilson PJ; Kuipers EJ; de Rooij FW
Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):449-59. PubMed ID: 17489054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
